Immunomodulation with FK506 around the time of intravenous re- administration of an adenoviral vector facilitates gene transfer into primed rat liver

International Journal of Cancer

Volumn 85, Issue 6, 2000, Pages 839-844

  Kuriyama, Shigeki ^a   Tominaga, Kentaro ^a   Mitoro, Akira ^a   Tsujinoue, Hirohisa ^a   Nakatani, Toshiya ^a   Yamazaki, Masaharu ^a   Nagao, Shintaro ^a   Toyokawa, Yasunori ^a   Okamoto, Shingo ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADENOVIRUS; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE TRANSFER; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYCLOPHOSPHAMIDE; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOSUPPRESSIVE AGENTS; LAC OPERON; LIVER; LYMPHOCYTE ACTIVATION; NEUTRALIZATION TESTS; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES; TACROLIMUS; TRANSGENES;

EID: 0034056004     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000315)85:6<839::AID-IJC17>3.0.CO;2-E     Document Type: Article

References (21)

1. ILAN, Y., SAUTER, B., ROY CHOWDHURY, N., REDDY, B.V.N., THUMMALA, N.R., DROGUETT, G., DAVIDSON, A., OTT, M., HORWITZ, M.S. and ROY CHOWDHURY, J., Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology, 27, 1368-1376 (1998).
2. JOOSS, K., TURKA, L.A. and WILSON, J.M., Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther., 5, 309-319 (1998).
3. KAPLAN, J.M. and SMITH, A.E., Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum. Gene Ther., 8, 1095-1104 (1997).
4. KANEGAE, Y., MAKIMURA, M. and SAITO, I., A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. med. Sci. Biol., 47, 157-166 (1994).
5. KURIYAMA, S., and 12 OTHERS, Cancer gene therapy with HSV-tk/GCV system depends on T cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int. J. Cancer (1999a) in press.
6. KURIYAMA, S., KIKUKAWA, M., MASUI, K., OKUDA, H., NAKATANI, T., SAKAMOTO, T., YOSHIJI, H., FUKUI, H., IKENAKA, K., MULLEN, C.A. and TSUJII, T., Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int. J. Cancer, 81, 592-597 (1999b).
7. KURIYAMA, S., SAKAMOTO, T., MASUI, K., NAKATANI, T., TOMINAGA, K., KIKUKAWA, M., YOSHIKAWA, M., IKENAKA, K., FLKUI, H. and TSUJII, T., Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int. J. Cancer, 71, 470-475 (1997).
8. KURIYAMA, S., TOMINAGA, K., KIKUKAWA, M., NAKATANI, T., TSUJINOUE, H., YAMAZAKI, M., NAGAO, S., TOYOKAWA, Y., MITORO, A. and FUKUI, H., Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res., 18, 2345-2351 (1998).
9. KURIYAMA, S., YOSHIKAWA, M., ISHIZAKA, S., TSUJII, T., IKENAKA, K., KAGAWA, T., MORITA, N. and MIKOSHIBA, K., A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct. Fund., 16, 503-510 (1991).
10. MACGREGOR, G.R., NOLAN, G.P., FIERING, S., ROEDERER, M. and HERZENBERG, L.A., Use of E. coli lac Z (β-galactosidase) as a reporter gene. In E.J. Murray (ed.), Methods in molecular biology, pp. 217-235, Humana Press, Clifton, NJ (1991).
11. MIYAKE, S., MAKIMURA, M., KANEGAE, Y., HARADA, S., SATO, Y., TAKAMORI, K., TOKUDA, C. and SAITO, I., Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. nat. Acad. Sci. (Wash.), 93, 1320-1324 (1996).
12. NAKAMURA, Y., WAKIMOTO, H., ABE, J., KANEGAE, Y., SAITO, I., AOYAGI, M., HIRAKAWA, K. and HAMADA, H., Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res., 54, 5757-5760 (1994).
13. NIWA, H., YAMAMURA, K. and MIYAZAKI, J., Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene, 108, 193-200 (1991).
14. ROSENECKER, J., HARMS, K.-H., BERTELE, R.M., POHL-KOPPE, A.V., MUTIUS, E., ADAM, D. and NICOLAI, T., Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Infection, 24, 5-8 (1996).
15. SMITH, C.A., WOODRUFF, L.S., ROONEY, C. and KITCHINGMAN, G.R., Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum. Gene Ther., 9, 1419-1427 (1998).
16. SMITH, T.A.G., WHITE, B.D., GARDNER, J.M., KALEKO, M. and MCCLELLAND, A., Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther., 3, 496-502 (1996).
17. WANG, Q., GREENBURG, G., BUNCH, D., FARSON, D. and FINER, M.H., Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔΕ1/ΔΕ4 adenovirus vector. Gene Ther., 4, 393-400 (1997).
18. WEINBERG, A., FINK, M.C., TAKIMOTO, S., ISHIDA, M.A. and SOUZA, M.C., Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population. Rev. Inst. Med. Trop. São Paulo, 31, 336-340 (1989).
19. YANG, Y., GREENOUGH, K. and WILSON, J.M., Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther., 3, 412-420 (1996).
20. YANG, Y., LI, Q., ERTL, H.C.J. and WILSON, J.M., Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol., 69, 2004-2015 (1995).
21. YEI, S., MITTEREDER, N., TANG, K., O'SULLIVAN, C. and TRAPNELL, B.C., Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther., 1, 192-200 (1994).